Kidney disease Archives

diabetes chronic kidney disease farxiga astraZeneca

News and Trends 8 Jun 2021

Farxiga’s Approval Fuels Chronic Kidney Disease Comeback

Until this year, there were no effective treatments for chronic kidney disease. However, the recent approval of AstraZeneca’s Farxiga alongside clinical breakthroughs and advances in precision medicine are causing the field to resurge. The last several months have seen big pharma companies scoring wins against chronic kidney disease (CKD). This condition involves gradual, irreversible kidney […]

June 8, 2021 - 5 minutesmins - By Jonathan Smith

News and Trends 31 Mar 2020

Update: AM-Pharma Increases Acute Kidney Injury Phase III Funds to €163M

Update (31/03/2020): AM-Pharma has raised an extra €47M on top of an existing €116M equity round to fund an upcoming phase III trial of a treatment for acute kidney injury. The money will help the Dutch biotech to prepare for its upcoming phase III trial of a protein drug for acute kidney injury, which is […]

March 31, 2020 - 3 minutesmins - By Jonathan Smith

News and Trends 13 Mar 2020

Immune Marker in Blood May Predict Kidney Transplant Rejection Risk

French researchers have found that the levels of certain immune cells in the blood of kidney transplant recipients may predict their future risk for transplant rejection. At present, kidney transplantation is the best treatment for people with end-stage renal disease but introducing a ‘foreign’ organ into someone’s body comes with the risk of rejection by […]

March 13, 2020 - 3 minutesmins - By Laura Cowen

Interview 18 Sep 2019

Why Communication is Key for Getting Ahead in Biotech

Many biotech founders and executives look to VC investors for advice and inspiration, but the attraction can go both ways. After more than a decade of investing in life science companies, Renee Aguiar-Lucander, now CEO of Calliditas Therapeutics, decided it was time to try sitting on the other side of the table. Prior to moving […]

September 18, 2019 - 11 minutesmins - By Helen Albert

News and Trends 29 Jul 2019

€43M Series C to Launch UK Company’s Home Hemodialysis Kit

Quanta Dialysis Technologies has raised €43.2M ($48M) to fund the commercial launch of a device that makes home hemodialysis more straightforward and economical for kidney failure patients. The UK-based Quanta will use the money to launch its technology in the UK later this year, and also apply for FDA approval. The technology previously obtained a […]

July 29, 2019 - 2 minutesmins - By Jonathan Smith

News and Trends 1 Mar 2019

Update: Hansa Biopharma Applies for EMA Market Approval for Kidney Transplant Drug

Update (01/03/2019): Hansa Biopharma (previously named Hansa Medical) has filed an application for marketing authorization for imlifidase with the EMA also for use in patients undergoing kidney transplants. Update (18/10/2018): Imlifidase has just been given Fast Track Designation by the FDA for application in transplantation. The designation should accelerate the treatment through the FDA’s regulatory process, with […]

March 1, 2019 - 3 minutesmins - By Jonathan Smith

medical university of vienna kidney transplant genomics

News and Trends 15 Feb 2019

Genetic Testing Improves Success of Kidney Transplants

Genetic variations in cell surface proteins are able to predict kidney transplant success, shows Austrian research, serving as a potential screening tool for improving future transplants. Many kidney transplants fail over time because the patient’s immune system rejects the organ. This rejection happens because the immune system recognizes that particular proteins on the cell surface, such […]

February 15, 2019 - 2 minutesmins - By Jonathan Smith

optofluid technologies kidney dialysis talinn

Startup Scout 16 Nov 2018

This Biotech Measures How Well Kidney Dialysis Machines Filter Your Blood

We take a hop, skip and a jump into Tallinn, Estonia this week. Optofluid Technologies is developing sensors that measure blood toxin levels to see how well dialysis procedures are working in kidney failure patients. Mission: To improve the effectiveness of dialysis in kidney failure patients. Optofluid’s experimental optical sensor could give physicians detailed real-time […]

November 16, 2018 - 3 minutesmins - By Jonathan Smith

News and Trends 12 Feb 2018

First Functioning Kidney Tissue Generated from Embryonic Stem Cells

Researchers at the University of Manchester have used embryonic stem cells to produce kidney tissue that can filter the blood to produce urine, which opens the door to personalized kidney transplants. Scientists at the University of Manchester have generated human kidney tissue from embryonic stem cells for the first time. The research, published in the journal Stem […]

February 12, 2018 - 3 minutesmins - By Alex Dale

balmes transplantation kidney disorders 1

News and Trends 6 Feb 2018

Say Hello to a New Biotech Striving to Prevent Kidney Damage During Surgery

Balmes Transplantation has raised €700,000 in seed funding to run a proof-of-concept study to test its drug combination for kidney damage. Balmes Transplantation is a young biotech in Marseille, France, that develops combination therapies for a common complication associated with kidney transplants and heart surgery. The biotech has raised a €700,000 seed funding from top company executives and angel […]

February 6, 2018 - 3 minutesmins - By Alex Dale

advicenne ipo rare disease children drta

News and Trends 6 Dec 2017

Update: French Biotech Closes €27M IPO to be the First to Treat Rare Disease in Children

Update (6/12/2017): Advicenne has raised a total of €27M on Euronext Paris, putting its market cap at €112M. Originally published on 21/11/2017 Advicenne is launching an IPO on Euronext Paris to raise the funds to bring the first treatment for dRTA, a rare disease of the kidneys, to the market. Advicenne, based in Nîmes, France, has officially […]

December 6, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

advicenne distal renal tubular acidosis rare disease

News and Trends 6 Nov 2017

Update: The First Drug for This Rare Kidney Disease May Come From a French Biotech

Update (6/11/2017): ADV7103 has maintained its efficacy in a 6-month extension of the Phase III study. In 79% of the patients, the blood bicarbonate levels were kept within the normal range after 6 months of treatment, further supporting its push to become the first treatment for the disease on the market. Originally published 11/9/2017 Advicenne has […]

November 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us